Navigation Links
China Nepstar Chain Drugstore Reports First Quarter 2011 Financial Results
Date:5/25/2011

ood-value private label products in convenience products category. In the first quarter, private label products' contribution to the convenience products category also reached 30.2%, helping maintain a reasonably favorable gross profit margin level on sales of convenience products.

Sales, marketing and other operating expenses as a percentage of revenue in the first quarter of 2011 decreased to 40.7% compared to 42.9% in the same period of 2010. This decrease from the same period of last year was primarily due to higher sales revenue generated from the diversification strategy and rigorous cost control measures.

General and administrative expenses as a percentage of revenue in the first quarter of 2011 were 5.1%, compared to 5.8% in the same period of 2010. The decrease was also due to cost control efforts and a higher revenue base in 2011.

As a result of the factors discussed above, income from operations in the first quarter of 2011 was RMB11.8 million (US$1.8 million), compared to a loss of RMB4.2 million in the same period of 2010. Operating margin was 1.9% in the first quarter of 2011.

Interest income for the first quarter of 2011 was RMB4.9 million (US$0.7 million), compared to RMB8.2 million in the same period of 2010. The decrease in interest income was mainly due to lower cash balances as a result of the dividend payments in 2010 and 2011, and share buyback program in 2010. Dividend income from cost method investments was RMB2.0 million (US$0.3 million), compared to that of RMB3.0 million in the same quarter of 2010. Equity income of an equity method investee was RMB1.0 million (US$0.2 million), compared to that of RMB1.8 million in the same quarter of 2010.

Nepstar's effective tax rate was 46.1% for the first quarter of 2011, compared to 66.8% for the same period in 2010. The decrease in effective tax rate was primarily because less valuation allowance was made for the deferred tax assets of loss-making subsidiaries due
'/>"/>

SOURCE China Nepstar Chain Drugstore Ltd.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Reportlinker Adds Drug Delivery Devices Market Outlook in China to 2017 - Metered Dose Inhaler Devices, Infusion Systems, Central Venous Catheters and Needle Free Injections
2. Business Monitor International Launches Report on Chinas Pharmaceutical and Healthcare Industry
3. China Shenghuo Pharmaceutical Reports Financial Results for the First Quarter of 2011
4. China Pharma Holdings, Inc. to Present at the Eighth Annual Piper Jaffray China Growth Conference in New York on May 17, 2011
5. Winner Medical to Present at Oppenheimer 5th Annual China Dragon Conference
6. Naviscan Announces Partnership With Chindex Medical Limited for Mainland China, Hong Kong and Macau
7. China New Borun Announces First Quarter 2011 Financial Results
8. China Pharma Holdings, Inc. Reports First Quarter 2011 Financial Results
9. Reportlinker Adds Orthopedic Devices Market in the Emerging Countries (China, India, Brazil) - Presenting New Avenues for Growth and Profitability
10. Saladax Biomedical, Inc. Announces Pacific Rim Commercialization Team in Australia and China
11. China Medical Technologies to Present at Jefferies 2011 Global Healthcare Conference on June 7, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... -- The new 13-valent pneumococcal conjugate vaccine (PCV13) appears ... prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), ... Vaccine. The U.S. Food and Drug Administration ... series of trials. These trials found that PCV13, which ... the previously used PCV7, did not increase the risk ...
(Date:5/22/2013)... , 22. Mai 2013 Kepner-Tregoe ... Beratung, gab heute bekannt, dass der Veteran ... , zum Hauptgeschäftsführer ernannt wurde. Geraghty,s ... Industriebereich wo er zahlreiche Führungspositionen bei Fertigungsunternehmen ... Baxter an, der als Kepner-Tregoe Hauptgeschäftsführer gedient ...
(Date:5/22/2013)... May 22, 2013  MGT Capital Investments, Inc. (NYSE ... at the Second Annual Marcum LLP MicroCap Conference on ... City at the Grand Hyatt Hotel.  ... Officer, will update investors and answer questions. ... presentation is scheduled to begin at 9:30 a.m. EDT.  ...
Breaking Medicine Technology:Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 2Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4
... The bio-pharmaceutical marketplace - and the Oncology therapeutic ... new medicines and technologies create valuable market opportunities. ... organizations with new Oncology products are scrutinizing their ... Commercial executives in the Oncology therapeutic area make ...
... 28 bioMerieux - a world leader in the ... announced the U.S. launch of chromID MRSA, a simple ... product recently received FDA 510(k) clearance for the detection ... high-morbidity healthcare-associated infections (HAI) in U.S. hospitals.(1) The current ...
Cached Medicine Technology:Educating the Marketplace to Support Successful Oncology Product Launches 2bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 2bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 3bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 4
(Date:5/22/2013)... 2013 Spinal Elements, an innovative ... in Carlsbad to 3115 Melrose Drive, Suite 200, ... company’s continued and projected growth and has expanded ... feet to over 40,000 square feet. , ... indicated, “Our investment in these state-of-the-art facilities will ...
(Date:5/22/2013)... Lawrenceville, NJ and Los Angeles, CA (PRWEB) May 22, ... chairman of the board, The J. M. Smucker Company, ... GS1 Lifetime Achievement Awards yesterday at the GS1 General ... Los Angeles, California. Mr. Smucker and Mr. Wegman were ... adoption of GS1 Standards - the most broadly used ...
(Date:5/22/2013)... -- Children who are physically, sexually or emotionally abused ... in life, a new review suggests. British researchers ... to be obese as adults. They concluded that child ... for obesity. "We found that being maltreated as ... adult life," study author Dr. Andrea Danese, a child ...
(Date:5/22/2013)... p53 turns off cancer. However, when existing drugs boost p53, only ... study published in the journal Cell Reports shows how: ... more of the protein p21 than the protein PUMA; tumors that ... the current study shows a handful of genes that control this ... mutated cancer genes. Tumors turn it off and then they can ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine . , The U.S. ... in 2010 after a series of trials. These trials ... of pneumococcal types than the previously used PCV7, did ...
Breaking Medicine News(10 mins):Health News:Spinal Elements®, Inc. Relocates Corporate Headquarters in Carlsbad 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Abused Children at Risk for Obesity as Adults: Study 2Health News:Study details genes that control whether tumors adapt or die when faced with p53 activating drugs 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
... Inc. (Amex:,ULU) announced today that Ronald A. Ahrens has ... Mr. Ahrens has been an advisor to Merck ... of Merck Consumer Healthcare Group Worldwide.,He had previously served ... From 1985 to 1990 Mr. Ahrens was Consumer,Group President, ...
... 23 The American Society of,Transplantation (AST) recently ... Award, to Richard N. Fine, M.D. at the,American ... a,senior investigator whose lifelong work has advanced the ... the field and the,AST have been broad and ...
... clot-busting tPA, researchers say , , MONDAY, June 23 (HealthDay ... boost stroke patients, survival, new research suggests. , Gleevec, ... as chronic myelogenous leukemia (CML), will be tested to ... the side effects of the clot-dissolving drug tissue plasminogen ...
... and Public Health Experts to Raise Public ... Awareness Via Mobile Media, ... HIV testing is getting out to the general public, thanks to,the ... most reliable wireless voice and data network,announced today its continued effort ...
... 23 Boston Scientific,Corporation (NYSE: BSX ) today ... will help service veterans and the active armed forces,better ... has recently,passed the Veterans Mental Health Improvements Act, which ... originally introduced,by Senator Daniel Akaka (D-HI). The bill calls ...
... Therapeutic Vaccines for Infectious ... Diseases, ... on emerging understanding of the human immune system,today announced the closing of ... Partners, The Column Group and Versant,Ventures. The Column Group initially incubated the ...
Cached Medicine News:Health News:ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors 2Health News:AST Awards Richard N. Fine, M.D. 2008 Ernest Hodge Distinguished Achievement Award 2Health News:Cancer Drug Gleevec Could Fight Stroke 2Health News:Cancer Drug Gleevec Could Fight Stroke 3Health News:Verizon Wireless Continues Support of National HIV Testing Awareness Campaign 2Health News:Verizon Wireless Continues Support of National HIV Testing Awareness Campaign 3Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 2Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 3Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 4Health News:Immune Design Announces $18 Million Series A Financing 2Health News:Immune Design Announces $18 Million Series A Financing 3
... Oximeter with SAC (Serial Autocorrelation) Technology uses ... extract SpO 2 , pulse strength, and ... This cost-effective compact monitor incorporates clinical, ... features, and a data log or trend ...
... Autocorr Plus, the fourth in the ... pulse oximeter/ECG/Respiration Monitor, with 3 or ... oximetry with SAC (Serial Autocorrelation) technology, ... screen display provides two user configurable ...
... The BCI 3180 Pulse Oximeter is a ... SpO 2 pulse rate and pulse ... adult. This AC or battery powered ... low alarm limits and up to 30 ...
... ReZoom intraocular lens is a second-generation refractive ... with greater independence from glasses than monofocal ... a range of vision that monfocals cannot ... technology distributes light over five optic zones ...
Medicine Products: